首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)
【2h】

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

机译:CYP2D6药代遗传学筛查在开始用去甲替林或文拉法辛治疗的老年人中的影响和成本效益:一项实用的随机对照试验(CYSCEtrial)的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundNortriptyline and venlafaxine are commonly used antidepressants for treatment of depression in older patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme and guidelines for dose adaptations based on the CYP2D6 genotype have been developed. The CYP2D6 Screening Among Elderly (CYSCE) trial is designed to address the potential health and economic value of genotyping for CYP2D6 in optimizing dose-finding of nortriptyline and venlafaxine.
机译:背景去甲替林和文拉法辛是用于治疗老年患者抑郁症的常用抗抑郁药。两种药物均通过多态性细胞色素P450-2D6(CYP2D6)酶代谢,并且已经开发了基于CYP2D6基因型的剂量适应指南。 CYP2D6老年人筛查(CYSCE)试验旨在解决CYP2D6基因分型在优化去甲替林和文拉法辛剂量方面的潜在健康和经济价值。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号